Literature DB >> 12975358

Cleavage of the ADAMTS13 propeptide is not required for protease activity.

Elaine M Majerus1, Xinglong Zheng, Elodee A Tuley, J Evan Sadler.   

Abstract

ADAMTS13 belongs to the "a disintegrin and metalloprotease with thrombospondin repeats" family, and cleaves von Willebrand factor multimers into smaller forms. For several related proteases, normal folding and enzymatic latency depend on an NH2-terminal propeptide that is removed by proteolytic processing during biosynthesis. However, the ADAMTS13 propeptide is unusually short and poorly conserved, suggesting it may not perform these functions. ADAMTS13 was secreted from transfected HeLa cells with a half-time of 7 h and the rate-limiting step was exported from the endoplasmic reticulum. Deletion of the propeptide did not impair the secretion of active ADAMTS13, indicating that the propeptide is dispensable for folding. Furin was shown to be sufficient for ADAMTS13 propeptide processing in two ways. First, mutation of the furin consensus recognition site prevented propeptide cleavage in HeLa cells and resulted in secretion of pro-ADAMTS13. Second, furin-deficient LoVo cells secreted ADAMTS13 with the propeptide intact, and cotransfection with furin restored propeptide cleavage. In both cell lines, secreted pro-ADAMTS13 had normal proteolytic activity toward von Willebrand factor. In cells coexpressing both ADAMTS13 and von Willebrand factor, pro-ADAMTS13 cleaved pro-von Willebrand factor intracellularly. Therefore, the ADAMTS13 propeptide is not required for folding or secretion, and does not perform the common function of maintaining enzyme latency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12975358     DOI: 10.1074/jbc.M309872200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.

Authors:  Jihui Ai; Paula Smith; Shuwei Wang; Ping Zhang; X Long Zheng
Journal:  J Biol Chem       Date:  2005-06-23       Impact factor: 5.157

Review 2.  Current concepts in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

3.  Stall encodes an ADAMTS metalloprotease and interacts genetically with Delta in Drosophila ovarian follicle formation.

Authors:  Emily F Ozdowski; Yvonne M Mowery; Claire Cronmiller
Journal:  Genetics       Date:  2009-09-14       Impact factor: 4.562

4.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

Review 5.  A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms.

Authors:  Suneel S Apte
Journal:  J Biol Chem       Date:  2009-09-04       Impact factor: 5.157

6.  ADAMTS13 and von Willebrand factor interactions.

Authors:  Catherine B Zander; Wenjing Cao; X Long Zheng
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

7.  Phylogenetic and functional analysis of ADAMTS13 identifies highly conserved domains essential for allosteric regulation.

Authors:  Joshua Muia; Jian Zhu; Suellen C Greco; Karen Vanhoorelbeke; Garima Gupta; Lisa A Westfield; J Evan Sadler
Journal:  Blood       Date:  2019-01-30       Impact factor: 22.113

8.  Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13.

Authors:  Kenji Nishio; Patricia J Anderson; X Long Zheng; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

Review 9.  The kidney in thrombotic thrombocytopenic purpura.

Authors:  H-M Tsai
Journal:  Minerva Med       Date:  2007-12       Impact factor: 4.806

10.  Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease.

Authors:  Zuben E Sauna; Chinyere Okunji; Ryan C Hunt; Tanvi Gupta; Courtni E Allen; Elizabeth Plum; Adam Blaisdell; Vahan Grigoryan; S Geetha; Robert Fathke; Kenji Soejima; Chava Kimchi-Sarfaty
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.